Effects of L-arginine Supplementation in Adults With Moderate to Severe Asthma

Completed · Phase 2 · Has a placebo group

Conditions studied: Asthma

In brief

Nitric oxide is an important marker of airway inflammation in asthma. Nitric oxide may have a protective role in patients with moderate to severe asthma. The investigators believe that a natural amino acid, L-arginine, that augments nitric oxide levels can decrease asthma exacerbations and improve the asthma care of moderate to severe asthma patients. This study is a randomized, placebo controlled trial in which subjects will receive either 3 months of L-arginine supplementation or a placebo. The investigators will monitor subjects' symptoms, the number of asthma exacerbations, and lung function. In addition, we will draw blood, obtain induced sputum samples and measure exhaled breath nitric oxide levels at each monthly visit.

Key facts

Study ID

NCT00280683

Run by

University of California, Davis

People needed

20

Starts

2004-12-01

Expected to finish

2008-12-01

Last updated by the study team

2017-05-30

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Moderate to severe persistent asthma
• Subject is stable on same asthma medications for at least one month
• If the subject is a woman of child-bearing age, a negative pregnancy test

You may not qualify if…

• Less than 18 yrs/ age
• Baseline Forced Expiratory Volume in 1 second (FEV1) <40% predicted
• Known or suspected allergy to L-arginine
• Pregnant women, nursing women, or women actively trying to achieve pregnancy
• Current smokers
• Subjects with more than a 15 pack-year history of smoking

Where it is running

• University of California, Davis General Clinical Research Center — Sacramento, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.